ALUMIS INC (ALMS)
Health Care · Biotechnology · NASDAQ
Alumis is a clinical-stage biopharmaceutical company developing targeted TYK2 inhibitors to transform the treatment of immune-mediated and neurodegenerative diseases.
What ALUMIS INC does
Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases, specifically aiming to replace broad immunosuppression. Its lead candidate is envu, a TYK2 inhibitor currently in clinical development for psoriasis and systemic lupus erythematosus. The company is also developing A-005, a CNS-penetrant TYK2 inhibitor for neurodegenerative conditions like Parkinson's disease.
Themes: immunology, TYK2 inhibitors, autoimmune disease therapy, neurodegeneration, clinical-stage biopharma
Fundamentals
- Price$24.17 as of 2026-08-21 close
- Market cap$3.1B as of 2026-08-24
- 1-year return+425.4% 2025-08-21 close $4.60 → 2026-08-21 close $24.17
- P/En/a negative earnings
- Net margin-1013.2% as of 2026-08-24
- ROE-54.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.72 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How ALMS compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ALMS is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
46.9 #995 of 1,704 scored · #173 of 240 in Health Care
Volume and participation 75th: it gapped 5.7% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; catalysts 62nd: analysts have raised their average price target by 0.6% since the prior reading; weakest is trend 30th: a trend forming but not yet strong (ADX below 25).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How ALUMIS INC looks technically
ALUMIS INC (ALMS) is trading 13.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 186 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 22.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 13.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +13.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.44 | $26.44 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $21.30 | $21.30 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 26.145. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 186 trading days ago — a "golden cross", a bullish long-term signal | 186 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($22.03 to $28.56) — its "stochastic" reading is 33 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 32.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 27 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $31.35 | $31.35 |
|---|---|---|
| From the 52-week high | it is 22.9% below its 52-week high (its highest price of the past year) | -22.9% |
| Above the 52-week low | it is 542.8% above its 52-week low (its lowest price of the past year) | +542.8% |
| Below the 52-week high | it is 22.9% below its highest point of the past year | 22.9% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $31.35 (set on 2026-07-08) | $31.35 |
| Given back of the 52-week move | over the past year its closes ranged ($3.95 to $30.30), and it has given back roughly a quarter of its rise from last year’s low — 23% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.17 to $14.02. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 23.3% |
| From the all-time high | it is 22.9% below its all-time high | -22.9% |
| Nearest price level | it is trading 9.0% below a resistance level at $26.35 — a price it turned at three times since 2026-03-26, most recently on 2026-07-15. Since 2024-08-21 it has 11 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +9.0% |
| All-time low | its lowest closing price on record is $2.76 (set on 2025-06-24) | $2.76 |
| Above the all-time low | it is 775.7% above its all-time low | +775.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 51st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.82 between its high and its low — about 7.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.82 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $23.03 and $29.27 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $23.03 – $26.15 – $29.27 |
| Typical daily range (% of price) | its price moves about 7.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.5% |
| Stretch from the 200-day average | it is trading 1.6 daily ranges above its 200-day average price (13.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.95× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.6% since the prior reading | +0.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 5.7% above the previous close 50 sessions ago and has not traded back through the level it left behind at 18.99 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.7% |
| Gap filled | a 2.4% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 21.9 percentage points (the stock lost 19.6% while the market gained 2.3%) | -21.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 5.9 percentage points (the stock gained 9.0% while the market gained 3.1%) | +5.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 24.7 percentage points (the stock lost 13.6% while the market gained 11.1%) | -24.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 405.0 percentage points (the stock gained 425.4% while the market gained 20.5%) | +404.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.4% of the share price. | -3.5% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $22.57 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +7.1% |
|---|
Price levels it has turned at before
ALMS last closed at $24.17 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $26.35 | Resistance | 9.0% above the last close | turned there three times · 2026-03-26 to 2026-07-15 |
| $28.30 | Resistance | 17.1% above the last close | turned there twice · 2026-01-29 to 2026-04-23 |
| $30.09 | Resistance | 24.5% above the last close | turned there twice · 2026-03-02 to 2026-07-21 |
| $13.05 | Support | 46.0% below the last close | turned there twice · 2024-10-21 to 2024-11-06 |
| $12.50 | Support | 48.3% below the last close | turned there twice · 2024-09-25 to 2025-12-10 |
| $10.43 | Support | 56.8% below the last close | turned there three times · 2024-09-16 to 2025-12-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $26.14.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $26.14 and $26.43 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Most volatile (6%+ typical daily range) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.30 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$40.33 range $25.00 – $55.00; median $39.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALMS
- Consensus EPS estimate-$0.75 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has no commercial products and has a history of significant operating losses with no assurance of future profitability.","Clinical development is subject to high failure rates, and any delays or negative trial results for envu or A-005 would severely impact the company's prospects.","Future financial success is dependent on obtaining regulatory approvals and successful commercialization of product candidates."]
What changed in the latest 10-Q
AI-assisted comparison of ALMS's 10-Q filed 2026-05-14 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K filed March 19, 2026 (newer filing) vs. March 19, 2025 (older filing)
- Statement that envu completed enrollment in pivotal Phase 3 ONWARD1 and ONWARD2 trials and reported positive topline results in Q1 2026
- Plan to submit NDA for envu in PsO in second half of 2026
- Statement that in May 2026, company completed strategic review of lonigutamab program and decided to explore strategic alternatives
- Net loss for three months ended March 31, 2026 was $93.1 million (compared to $99.0 million in 2025)
- Accumulated deficit as of March 31, 2026 was $994.9 million
- Specific bullet point: 'prepare to submit an NDA for envu in PsO in the second half of 2026, including as we conduct activities, including CMC activities, that are required to complete our planned NDA submission'
- Reference to 'Kaken Collaboration Agreement' in expense section
- Removed:
- Reference to Form 10-K filed March 19, 2025 (older filing)
- Descriptive phrase 'envudeucitinib (or "envu"), formerly known as ESK-001' - simplified to just 'envu' in newer filing
- Statement that 'Envu has demonstrated significant therapeutic effect in our Phase 2 program in patients with moderate-to-severe plaque psoriasis'
- Statement about having 'initiated our Phase 3 ONWARD clinical program' with expectation to report results 'early in the first quarter of 2026'
- Detailed description of ONWARD3 as long-term extension study within Phase 3 program
- Description of A-005 as 'allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases'
- Statement 'We are continuing to evaluate the development program for lonigutamab and its potential differentiation in a capital efficient manner'
- Paragraph on funding sources: 'To date, we have primarily funded our operations primarily through issuance of common stock...'
- Net loss figures for nine months ended September 30, 2025 and 2024 ($110.8 million, $93.1 million, $150.4 million, $199.5 million respectively)
- Accumulated deficit figure of $808.9 million as of September 30, 2025
- Statement about 'substantial expenses associated with the ACELYRIN Merger and the integration and development activities'
- Phrase 'that we did not incur as a private company' describing public company costs
- Bullet point: 'continue committing substantial capital resources to the integration and development activities related to the acquired ACELYRIN business'
- Reference to 'FronThera Acquisition agreement' and 'Pierre Fabre Agreement' (older version) vs. 'FronThera Acquisition' and 'Pierre Fabre Agreement' (newer version)
- Reworded:
- Opening reference changed from 'unaudited interim condensed consolidated financial statements' to 'unaudited condensed consolidated financial statements'
- Longer clinical program description simplified: older version described Phase 2 results, Phase 3 ONWARD program initiation, and ONWARD3 LTE study; newer version describes Phase 3 ONWARD1 and ONWARD2 completion with positive topline results and separate Phase 3 LTE trial
- Changed from future tense about Phase 3 topline results to past tense: 'reported positive topline results in the first quarter of 2026'
- Description of lonigutamab program changed from 'continuing to evaluate...in a capital efficient manner' to 'completed strategic review and decided to explore strategic alternatives'
- Expense bullet points reordered and refined; removed ACELYRIN-specific integration language and added NDA submission language
- Notes:
- The two filings cover different fiscal periods (Q1 2026 vs. Q3 2025), which accounts for some content differences
- The text provided appears truncated at the end of both sections, limiting full comparison of the complete MD&A
Risk Factors
- Added:
- Added new risk bullet point in summary: 'We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, rules; contractual obligations; policies; and other obligations related to data privacy and security...' (filed 2026-05-14)
- Added language 'and licensees' to patent protection risk: 'We cannot ensure that patent rights relating to inventions described and claimed in our or any current or future licensors' and licensees' pending patent applications...' (filed 2026-05-14)
- Removed:
- Removed risk bullet point from summary: 'We are subject to various risks related to the acquisition of ACELYRIN.' (was in 2025-11-13 filing)
- Removed parenthetical reference: ', formerly known as ESK-001,' from product candidate description (was in 2025-11-13 filing)
- Removed abbreviation reference: '("MS")' from multiple sclerosis description (was in 2025-11-13 filing)
- Removed text 'or seek' from collaboration risk: 'We have and may continue to form or seek collaborations' vs. older 'We may form or seek collaborations' (filed 2026-05-14)
- Removed text 'or collaborators' from conflicts risk bullet: older version said 'licensors or collaborators' but newer says 'licensors, licensees, collaborators or strategic partners' (filed 2026-05-14)
- Reworded:
- Changed clinical trial description from 'two parallel Phase 3 clinical trials of envu in PsO' to 'a Phase 2 open-label extension trial, as well as a Phase 3 LTE trial of envu in PsO' (filed 2026-05-14)
- Changed SAE/AE risk description from 'not seen in our preclinical studies or prior clinical trials' to remove that qualifying phrase (filed 2026-05-14)
- Changed collaboration risk language from 'We may form or seek collaborations' to 'We have and may continue to form or seek collaborations' (filed 2026-05-14)
- Expanded collaboration risk scope from 'licensors, licensees, collaborators' to add 'strategic partners' (filed 2026-05-14)
- Notes:
- The newer filing (2026-05-14) text provided is truncated mid-sentence at 'Phase 1 clinical devel', limiting full assessment of complete changes
- Older filing (2025-11-13) financial data reference appears partially in excerpt but not fully comparable to newer filing due to truncation
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 6 sells ($394311) — 6 selling insiders
- Last 90 days0 buys · 7 sells ($534311) — 6 selling insiders
- Last 180 days0 buys · 7 sells ($534311) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALMS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ALMS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,591,336
- Reported value $233,327,133
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ALMS had 5,766,070 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for ALMS because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 5,766,070
- Prior settlement (shares) 6,764,417
- Reported change -14.76%
- Days to cover (reported) 6.11
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- AbbVie (ABBV)
- Galapagos (GLPG)
- Amgen (AMGN)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALMS vs…
ALUMIS INC is found in…
Frequently asked questions
What does ALUMIS INC (ALMS) do?
Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases, specifically aiming to replace broad immunosuppression. Its lead candidate is envu, a TYK2 inhibitor currently in clinical development for psoriasis and systemic lupus erythematosus. The company is also developing A-005, a CNS-penetrant TYK2 inhibitor for neurodegenerative conditions like Parkinson's disease.
What sector is ALUMIS INC (ALMS) in?
ALUMIS INC (ALMS) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ALUMIS INC's (ALMS) competitors?
Notable peers of ALUMIS INC (ALMS) include Bristol Myers Squibb, AbbVie, Galapagos, Amgen and Pfizer. This peer set is informational only — not financial advice.
Is ALUMIS INC (ALMS) overbought or oversold right now?
ALUMIS INC (ALMS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALMS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.